Clinical Impact of New Data From Boston 2016

November 11-15, 2016; Boston, Massachusetts
In this Expert Analysis, Ira M. Jacobson, MD, and Stefan Zeuzem, MD, provide expert interpretation of the most clinically important new data on HCV, HBV, and NASH from this important annual conference.
Ira M. Jacobson, MD
Stefan Zeuzem, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Released: February 1, 2017 Expiration: January 31, 2018

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate the results of recent clinical studies of approved HCV, HBV, and other liver disease therapies into patient management strategies
  • Evaluate the impact of results of clinical studies of investigational treatments for chronic hepatitis C and B on future patient management strategies
  • Implement new data on strategies for diagnosing and managing NAFLD/NASH
  • Incorporate the results of recent studies into the prevention and management of the clinical sequelae of advanced liver disease

Acknowledgements

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
Merck & Co., Inc.
Gilead Sciences
AbbVie

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Ira M. Jacobson, MD

Chair, Department of Medicine
Mount Sinai Beth Israel
Professor of Medicine and Vice-Chair, Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Ira M. Jacobson, MD, has disclosed that that he has served as a consultant or on advisory boards for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Intercept, Janssen, Merck, and Trek; has served on speaker bureaus for AbbVie, Gilead Sciences, Intercept and Merck; and has received funds for research support from AbbVie, Gilead Sciences, Genfit, and Merck.

Stefan Zeuzem, MD

Professor of Medicine
Chief, Department of Medicine I
JW Goethe University Hospital
Frankfurt, Germany

Stefan Zeuzem, MD, has disclosed that he has served as a consultant or on advisory boards for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Roche.

Staff

Megan K. Murphy, PhD

Clinical Editor

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
Zachary Schwartz, MSc, ELS

Managing Editor

Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Charles E. Willis, MBA, Director of Continuing Education, Amanda Sewell, MBA, Manager of Continuing Education, and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians including infectious diseases specialists, hepatologists, and gastroenterologists, registered nurses, and other healthcare professionals involved in the care of patients with liver disease.

Goal

The goal of this activity is to improve participants’ competence in translating the most clinically significant hepatology data from the Boston 2016 conference into practical management strategies for patients with liver diseases.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation

1.0 contact hour may be earned for successful completion of this activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 01, 2017, through January 31, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

Related Content

Expert HBV management review, including treatment candidacy, preferred treatment options, and antiviral resistance and advanced liver disease management.

Stefan Zeuzem, MD
Program Director
Harry L. A. Janssen, MD, PhD Milan J. Sonneveld, MD, PhD, MSc
Released: June 21, 2018

Stefan Zeuzem, MD
Program Director
Jordan J. Feld, MD, MPH Hemant Shah, MD, MScCH HPTE
Released: June 15, 2018

When and how to treat hepatitis B infection in women of childbearing age, in early pregnancy, and in late pregnancy.

Natalie H. Bzowej, MD, PhD Released: June 8, 2018

Expert blog from Dr. Zobair M. Younossi offering perspective on new HCV and NAFLD/NASH data from the 2018 EASL International Liver Congress in Paris.

Zobair Younossi Headshot Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD Released: June 4, 2018

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?